早期乳腺癌前哨淋巴结活检在简化腋清扫中的应用研究

[目的]探讨早期乳腺癌患者行前哨淋巴结活检（SLNB）为阴性,行简化腋窝淋巴结清扫替代腋窝淋巴结清扫术（ALND）的临床效果。[方法]采用1%亚甲蓝染色法对65例早期乳腺癌患者行SLNB,60例成功行SLNB,其中40例SLN无转移者行简化腋窝淋巴结清扫术（简化组）;20例SLN有转移者行ALND（标准组）,比较两组患者术后上肢并发症的发生情况、腋窝复发及全身转移情况。[结果]简化组手术时间和腋窝引流时间比标准组明显缩短,有统计学差异（P〈0.01）;简化组术后患侧上肢的疼痛、肿胀、麻木症状明显较标准组少（P〈0.01）。两组生存曲线没有差异。[结论]亚甲蓝染色法能够比较准确地定位乳腺癌的前哨淋巴结。简化ALND替代ALND手术时间和术后引流时间缩短,方便可行,并发症明显减少,腋窝复发率低,是早期乳腺癌患者的安全分期手术。     

乳腺癌前哨淋巴结活检

慨述乳腺癌前哨淋巴结活检(SLNB)的解剖生理基础、临床意义、影响因素、假阴性和乳腺癌前哨淋巴结的定位、微转移及病理诊断。SLNB常规应用于临床还有持进一步探讨。     

早期乳腺癌前哨淋巴结活检替代腋窝淋巴结清扫的临床应用研究

目的 对前哨淋巴结活检(sentinel lymph node biopsy,SLNB)替代腋窝淋巴结清扫(axillary lymph node dis-section,ALND)在早期乳腺癌患者中的应用以及安全性研究及探讨.方法 回顾性分析行SLNB和ALND手术的503例早期乳腺癌病例,对患者住院时间、拔管时间及住院费用进行对比,以及对患者上肢并发症、腋窝局部复发及远处转移情况进行随访,随访至2016年06月,中位随访时间为32(6 ～52)个月.结果 在住院时间、拔管时间、住院费用以及上肢并发症方面,SLNB组明显优于ALND组,差异有统计学意义,而在腋窝局部复发及远处转移情况方面两组无统计学意义.结论 在SLN阴性早期乳腺癌中,SLNB与ALND可以取得相同的疗效,而且,SLNB与ALND相比,手术创伤小,麻木疼痛、肩关节活动受限等术后并发症明显减少,且可缩短患者住院时间,减轻患者的经济负担.     

Sentinel Node Biopsy in Early Breast Cancer Patients with Palpable Axillary Node

Background: Sentinel lymph node biopsy is a reliable method for evaluation of the axillary lymph node status in early stage breast cancer patients with non-palpable lymph nodes. The present study evaluated the status of sentinel and non-sentinel lymph nodes in T1T2 patients with palpable axillary lymph nodes. Materials and Methods: One hundred and two women with early breast cancer were investigated in this study. Patients were selected for axillary sentinel lymph node biopsy and then surgery .Then the rates of false negative and true positive, and diagnostic accuracy of sentinel lymph nodes biopsy were evaluated. In addition, the hormone receptors status of the tumor was determined through IHC and data was analyzed in SPSS21. Results: In this study, the mean age of the patients was 49 years, 85% had invasive ductal carcinoma  in their pathology reports, 77% were ER/PR positive, 30% HER2 positive and 9.8% triple negative and 69% had KI67<14%. In frozen pathology, 15.7 and 84.3% were sentinel positive and negative, respectively, and in the final pathology, 41 and 58.8% were sentinel positive and negative, respectively. This difference arises from the false negative rate of the frozen pathology, which was about 31.3%. The sensitivity, specificity, and diagnostic accuracy of the frozen section were 24, 90 and 43%, respectively. Lymphovascular invasion is an important effective factor in the involvement of sentinel and non-sentinel lymph nodes. Statistical analysis showed that the probability of sentinel and non-sentinel lymph nodes involvement was higher in receptor positive patients and those with KI67>14% (p<0.002) whereas the rate of involvement was lower in triple negative patients. Conclusion: Sentinel node biopsy can be used in a significant percentage of breast cancer patients with palpable and reactive axillary lymph nodes.     

早期乳腺癌中前哨淋巴结导航的淋巴结群切除的价值

[目的]比较腋窝前哨淋巴结（SLN）导航的淋巴结群切除与单纯前哨淋巴结活检（SLNB）的优劣,探讨其作为早期乳腺癌外科腋窝处理手段的可行性及临床意义。[方法]2003年10月至2009年5月．连续入组305例早期乳腺癌手术病例,术中序贯施行腋窝SLNB、SLN所在淋巴结群切除及全腋窝淋巴结清扫（ALND）,比较SLNB与SLN导航的淋巴结群切除活检预测腋淋巴结状态的差异并分析影响淋巴结状态的因素。[结果]SLNB成功率为99.34％（303／305）。SLNB假阴性10例,SLNB预测淋巴结状态假阴性率为9．80％（10／102）、敏感性90．20％（92／102）、准确性96．70％（293,303）、阴性似然比0．098。SLN导航的淋巴结群切除活检预测腋淋巴结状态的假阴性率为1．96％（2／102）、敏感性98．04％（100／102）、准确性99．34％（301／303）、阴性似然比0．020。淋巴结状态与肿瘤大小、脉管浸润、组织学分级及Her-2状态相关（P〈0．05）。[结论]以腋窝SLN导航的淋巴结群切除替代ALND治疗早期乳腺癌较单纯SLNB更具安全性及应用价值。结合肿瘤大小、脉管浸润、组织学分级及Her-2状态有助于更准确地指导腋窝淋巴结处理方式.     

Current Controversies Concerning Sentinel Lymph Node Biopsy for Breast Cancer

BACKGROUND AND METHODS: The objectives of this article are to review existing controversies regarding sentinel lymph node (SLN) biopsy and to identify potential areas of consensus in order to eliminate routine axillary lymph node dissection (ALND). RESULTS: A combination of peritumoral injection with radioisotopes and subdermal or subareolar injection with blue dye may result in enhanced success rates of SLN identification. Preoperative lymphoscintigraphy is most useful for detecting an internal mammary SLN, but the practicability of internal mammary SLN biopsy is still in the investigative stage. Intraoperative diagnosis of SLN is useful because patients with SLN metastases may be treated immediately with ALND, but it is unreasonable to expect that either examination of frozen sections or imprint cytology will detect every metastatic disease. SLN micrometastases may be of prognostic importance and these can be identified with H and E staining on permanent sections of 200 micro m intervals. While ALND is preferable for patients even with a small tumor (T1) and SLN micrometastases, radiation therapy is an acceptable alternative. SLN biopsy may be indicated for patients with DCIS detected as a palpable mass or those with large calcification areas in the breast. The accuracy of SLN biopsy after neoadjuvant chemotherapy is considered to be unproven. CONCLUSION: Since SLN biopsy has been adopted by surgeons around the world, consistency of technique and case selection has attained great significance.     

Comparing Early-Stage Breast Cancer Patients with Sentinel Lymph Node Metastasis with and without Completion Axillary Lymph Node Dissection: A Systematic Review and Meta-Analysis

Background: Currently, the standard method for staging and treatment of axillary lymph nodes for early-stage breast cancer is sentinel lymph node biopsy (SLNB), while axillary lymph node dissection (ALND) is used in cases with palpable axillary lymph nodes or positive SLNB cases. The aim of this review was to compare overall survival (OS), disease-free survival (DFS), and axillary recurrence in early-stage breast cancer patients underwent SLNB or SLNB and completion ALND. Methods: The databases of PubMed, Scopus, and Cochrane Library were searched using the key words of “breast cancer”, “axillary lymph node dissection”, and “sentinel lymph node dissection”. In addition, other sources were searched for ongoing studies (i.e., clinicaltrials.gov). The clinical trials were evaluated based on the Jadad quality criteria, and cohort studies were evaluated according to the STROBE criteria. At the end of the search, the articles were screened independently by two reviewers to check their eligibility to be included in the study. Afterwards, the data were extracted independently by two researchers. Results: After searching the databases, 169 papers were retrieved. However, after removing the duplicates and studying the titles and abstracts of these papers, only ten ones underwent further investigation. After reading full-text of each article, four studies were finalized. Following a manual search, 27 papers were entered into the study for the final evaluation, 11 of which were included in the meta-analysis based on the inclusion and exclusion criteria. The findings showed no significant differences in OS, DFS, and axillary recurrence in early-stage breast cancer patients underwent SLNB or SLNB and completion ALND. Conclusion: The findings did not confirm that ALND improved OS, DFS, and axillary recurrence in patients who were clinically node-negative and positive SLNB.     

乳腺癌前哨体淋巴结活检的研究

前哨淋巴结(SLN)的概念和前哨淋巴结活检(SLNB)的应用是在1977年被提出的,但由于当时淋巴结检测设备和技术尚不先进,使SLN的研究未能得到足够的重视.乳腺癌SLNB是在20世纪90年代兴起的,现已成为乳腺癌外科领域的研究热点,有望在早期乳腺癌治疗中取代常规的腋窝淋巴结解剖(ALND),降低上肢淋巴水肿和功能障碍的发生率.我国该项目研究起步较晚,目前已逐渐成为人们关注的热点.该项目还将继续进行多中心、大样本、前瞻性研究,最终达成共识,将给乳腺癌病人带来福音.     

Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Initial Axillary Lymph Node Metastasis after Primary Systemic Therapy

Purpose

Primary systemic therapy (PST) downstages up to 40% of initial documented axillary lymph node (ALN) metastases in breast cancer. The current surgical treatment after PST consists of breast tumor resection and axillary lymph node dissection (ALND). This strategy, however, does not eliminate unnecessary ALND in patients with complete remission of axillary metastases. The aim of this study was to examine the accuracy of sentinel lymph node biopsy (SLNB) after PST among patients with documented ALN metastasis at presentation and to identify the rate of pathologic complete-remission (CR) with ALN after PST.

Methods

We analyzed 66 patients with ALN metastasis that was pathologically proven preoperatively who underwent SLNB and concomitant ALND after PST. Axillary ultrasound (AUS) was used to evaluate the clinical response of initially documented ALN metastasis after PST. Intraoperative lymphatic mapping was performed using blue dye with or without radioisotope.

Results

After PST, 34.8% of patients had clinical CR of ALN on AUS and 28.8% patients had pathologic CR of ALN. The overall success rate of SLNB after PST was 87.9%, and the sentinel lymph node identification rate in patients with clinical CR was 95.7%. In patients with successful lymphatic mapping, 70.7% of patients had residual axillary metastases. The overall accuracy and false-negative rate were 87.9% and 17.1% in all patients: 95.5% and 10.0% in patients with clinical CR of ALN, and 83.3% and 19.4% in patients with residual axillary disease after PST.

Conclusion

Our findings suggest that SLNB may be feasible in patients with initial documented ALN metastasis who have clinical CR for metastatic ALN after PST. Further investigation in a prospective setting should be performed to confirm our results.     

Number of Metastatic Sentinel Nodes As Predictor of Axillary Involvement in Patients with Breast Cancer

BACKGROUND AND OBJECTIVES: More than half of patients with positive sentinel node (SN) have no metastases in non-sentinel nodes (NSNs) on axillary lymph node dissection (ALND). The aim of this study was to investigate factors predictive of NSNs involvement, in order to identify patients with metastatic disease confined to the SN which might avoid ALND. METHODS: ALND was performed in 167 patients with metastatic SN. Axillary NSNs status was correlated with the size of SN metastases, the size of the primary tumor and the occurrence of lymphovascular invasion. In 72 cases, the radiotracer (Tc-99m albumin colloid) marked multiple (in most cases 2 or 3) nodes. In this group, NSNs status was correlated with the number of metastatic radioactive nodes (1 or > 1), and with the above mentioned histopathologic factors. RESULTS: NSNs metastases were found in 57/167 cases (34.1%), the rate increasing proportionate to the size of both SN metastases (p < 0.0001) and primary tumor (p = 0.0075), while no significant correlation was found for lymphovascular invasion (p = 0.1769). At univariate and multivariate analysis of findings from the 72 cases with multiple probe-detected hot nodes, positivity in more than one hot node was the strongest predictor of NSN involvement (p = 0.0019). CONCLUSIONS: The identification and excision of multiple hot nodes can be useful in the prediction of NSNs involvement in patients with metastatic SN.     

Value of Sentinel Lymph Node Biopsy in Breast Cancer Surgery with Simple Pathology Facilities -An Iranian Local Experience with a Review of Potential Causes of False Negative Results

Introduction: Sentinel lymph node biopsy (SLNB) is a precise procedure for lymphatic staging in earlybreast cancer. In a valid SLNB procedure, axillary lymph node dissection (ALND) can be omitted in nodenegativecases without compromising patient safety. In this study, detection rate, accuracy and false negativerate of SLNB for breast cancer was evaluated in a setting with simple modified conventional pathology facilitieswithout any serial sectioning or immunohistochemistry. Material and Method: Patients with confirmed breastcancer were enrolled in the study. SLNB and ALND were performed in all cases. Lymph node metastasis wasevaluated in SLN and in nodes removed by ALND to determine the false negative rate. Pathologic assessmentwas carried out only by modified conventional technique with only 3 sections. Detection rate was determinedeither by lymphoscintigraphy or during surgery. Results: 78 patients with 79 breast units were evaluated. SLNwas detected in 75 of 79 cases (95%) in lymphoscintigraphy and 76 of 79 cases (96%) during surgery. SLNmetastases was detected in 30 of 75 (40%) cases either in SLNB and ALND groups. Accuracy of SLNB methodfor detecting LN metastases was 92%. False negative rate was 3 of 30 of positive cases: 10%. In 7 of 10 cases withaxillary lymphadenopathy, LN metastastates was detected. Conclusion: SLNB is recommended for patients withvarious tumor sizes without palpable lymph nodes. In modified conventional pathologic examination of SLNs,at least macrometastases and some micrometastases could be detected similar to ALND. Consequently, ALNDcould be omitted in node-negative cases with removal of all palpable LNs. We conclude that SLNB, as one of themost important developments in breast cancer surgery, could be expanded even in areas without sophisticatedpathology facilities.     

前哨淋巴结活检阴性乳腺癌患者行低位部分腋窝淋巴结清扫的必要性探讨

目的 探讨前哨淋巴结活检（sentinel lymph node biopsy, SLNB）阴性行低位部分腋窝淋巴结清扫（low partial axillary lymph node dissection, LPALND）的必要性。方法 收集138例影像学检查提示腋窝淋巴结肿大、SLNB阴性（≤4枚）并进一步行LPALND乳腺癌患者临床病理资料进行回顾性分析,探讨患者行LPALND的必要性。结果 SLNB 2枚组、3枚组与4枚组发生LPALN转移概率比较差异均无统计学意义（P>0.05）。但1枚组与4枚组发生LPALN转移概率比较差异有统计学意义（P<0.05）。结论 对影像学检查提示腋窝淋巴结肿大行SLNB 1枚阴性患者应行LPALND, 2~3枚阴性患者建议行LPALND,4枚阴性患者可免于行LPALND。     

美蓝在乳腺癌前哨淋巴结活检中的临床价值

目的探讨美蓝在乳腺癌前哨淋巴结活检中的临床价值。方法将1%美蓝2ml注入活检腔外上方的皮下及乳腺组织内,然后行Auchincloss仿根治术,依淋巴管走向找到蓝染淋巴结定为SLN,若此时未找到待腋窝清扫结束后,再在标本中寻找,蓝染者为SLN,余为非SLN,分别送病理检查。结果前哨淋巴结检出率为87.9%(95/108),SLN预测腋窝状况的准确率为95.7%(91/95),假阴性率为6.5%(4/62),无假阳性者。未检出者13例,其中4例为假阴性,均属跳跃式转移。前哨淋巴结转移阳性率(34.6%,33/95)和阴性率(65.3%,62/95),与全腋淋巴结转移阳性率(39.8%,43/108)和阴性率(60.2%,65/108)比较,均无显著性差异(P>0.05)。结论美蓝前哨淋巴结活检可以准确预测乳腺癌患者的腋淋巴结状态。     

术前淋巴结显像在乳腺癌前哨淋巴结活检中的应用价值

[目的]探讨术前淋巴显像在乳腺癌前哨淋巴结活检中的应用价值。[方法]回顾性分析2010年7月至2013年8月在河南省肿瘤医院行前哨淋巴结活检术的乳腺癌患者1041例,其中483例患者术前行淋巴结显像,558例患者未行淋巴显像而术中直接行前哨淋巴结活检术。[结果]在淋巴显像组中,84.3％（407／483）的患者显像成功,该组SLNB的成功率为98．9％（478／483）。而在未行淋巴显像组中SLNB的成功率为98．7％（551／558）。两组SLNB检出成功率差异无统计学意义（P=0．78）。即使术前淋巴显像失败,其SLNB的检出成功率仍达到98．7％。[结论]术前淋巴显像并不能提高SLNB的成功率。因此,临床工作中行前哨淋巴结活检前,淋巴显像不是必备条件。     

Sentinel Lymph Node Identification in Endometrial Cancer

OBJECTIVE To evaluate the feasibility of intra-operative detection of sentinel lymph nodes (SLN) in the patient with endometrial cancer (EC).METHODS Thirty-one patients with Stage Ⅰ and Ⅱ endometrial cancer, who underwent a hysterectomy and a lymphadenectomy,were enrolled in the study. At laparotomy, methylene blue dye tracer was injected into the subserosal myometrium of corpus uteri at multiple sites, and dye uptake into the lymphatic channels was observed. The blue nodes which were identified as SLNs were traced and excised. The other nodes were then removed. All of the excised nodes were submitted for pathological hematoxylin and eosin (H&E) staining examination.RESULTS Failure of dye uptake occurred in 4 of the 31 cases (12.9%) because of spillage, and no lymphatic coloration was observed there. Lymphatic staining was clearly observable as blue dye diffused to the lymphatic channels of the uterine surface and the infundibulopelvic ligaments in 27 (87.1%) cases. Concurrent coloration in the pelvic lymphatic vessels was also observed in 22of the 27 patients. The SLNs were identified in 23 of the 27 (85.2%)cases with a lymphatic staining, with a total number of 90 SLNs,and a mean of 3.9 in each case (range, 1-10). Besides one SLN (1.1%)in the para-aortic area, the other 89 (98.9%) were in the nodes of the pelvis. The most dense locations of SLNs included obturator in 38 (42.2%) and interiliac in 19 (21.1%) cases. In our group, pelvic lymphadenectomy was conducted in 27 (87.1%) patients and pelvic nodal sampling in 4 (12.9%). Of the 31 cases, a concurrent abdominal para-aortic lymph node sampling was conducted in 7. A total of 926 nodes were harvested, with an average of 39.8 in each case (range, 14-55). Nodal metastases occurred in 3 patients (9.7%), 2 of them with SLN involvement and the other without SLN involvement. Adverse reactions or injury related to the study was not found.CONCLUSION Application of methylene blue dye is feasible in an intra-operative SLN identification of endometrial cancer. The technology is convenient, safe, and worth further investigation.     

Clinical Significance of the Axillary Arch in Sentinel Lymph Node Biopsy

Purpose

The axillary arch is an anomalous muscle that is not infrequently encountered during axillary sentinel lymph node biopsy (SLNB) of breast cancer patients. In this study, we aimed to investigate how often the axillary arch is found during SLNB and whether it affects the intraoperative sentinel lymph node (SLN) identification rate.

Methods

We retrospectively analyzed the correlation between the presence of the axillary arch and the SLN sampling failure rate during SLNB in 1,069 patients who underwent axillary SLNB for invasive breast cancer.

Results

Of 1,069 patients who underwent SLNB, 79 patients (7.4%) had the axillary arch present. The SLNB failure rate was high when the patient''s body mass index was ≥25 (p=0.026), when a single SLN mapping technique was used (p=0.012), and when the axillary arch was present (p<0.001). These three factors were also found to be statistically significant by multivariate analysis, and of these three factors, presence of the axillary arch most significantly increased the SLNB failure rate (hazard ratio, 10.96; 95% confidence interval, 4.42-27.21; p<0.001). Additionally, if the axillary arch was present, the mean operative time of SLNB was 20.8 minutes, compared to 12.5 minutes when the axillary arch was not present (p<0.001). If the axillary arch was present, the SLN was often located in a high axillary region (67%) rather than in a general low axillary location.

Conclusion

The axillary arch was found to be a significant factor affecting intraoperative SLN failure rate. It is necessary to keep in mind that carefully checking the high axillar region during SLNB in breast cancer patients with the axillary arch is important for reducing SLN sampling failure.     

Reliability of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients

Purpose

Sentinel lymph node biopsy (SLNB) is an accurate and effective means of axillary nodal staging in early breast cancer. However its indication after neoadjuvant chemotherapy (NAC) is under constant debate. The present study evaluates the reliability of SLNB in assessing axillary nodal status after NAC.

Methods

Data from 281 patients who had received NAC and subsequent SLNB were reviewed. The identification and false negative rates of SLNB were determined and the clinicopathologic factors associated with false negative results were investigated using univariate analysis.

Results

The identification rate of SLNB after NAC was 93.6% and the false negative rate was 10.4%. Hormone receptor status, especially progesterone receptor positivity, was significantly associated with false negative results. The accuracy of intraoperative frozen section examination of sentinel lymph nodes was 91.2%.

Conclusion

The identification rate of SLNB and the accuracy of intraoperative frozen section examination after NAC are comparable to the results without NAC in patients with early breast cancer. However considering the high false negative rates, general application of SLNB after NAC should be avoided. Patients with progesterone-positive tumors and non-triple-negative breast cancers may be a select group of patients in whom SLNB can be employed safely after NAC, but further studies are necessary.     

29例宫颈癌前哨淋巴结检测分析

[目的]使用亚甲蓝作为示踪剂检测宫颈癌前哨淋巴结,观察安全性并分析影响检测的因素。[方法]2004年1月至2005年1月,采用亚甲蓝检测29例Ⅰb～Ⅱb期宫颈癌前哨淋巴结。根据术后病理判断用前哨淋巴结预测盆腔淋巴结转移的准确性和假阴性率。[结果]29例中,23例成功定位出前哨淋巴结41枚,总检出率为79.31%。其中术前未行化疗者检出率为80.00%,行化疗者检出率为79.17%。最多见检出部位为闭孔淋巴结。[结论]染料法宫颈癌前哨淋巴结定位是安全的,检出部位以闭孔窝最多见。     

Sentinel Lymph Node Biopsy Alone after Neoadjuvant Chemotherapy in Patients with Initial Cytology-Proven Axillary Node Metastasis

Purpose

Neoadjuvant chemotherapy (NAC) has been recently used to downstage breast cancer. However, in patients with initial axillary lymph node (ALN) metastasis, ALN dissection regardless of the NAC response remains the standard treatment. The purpose of this study was to identify the feasibility and accuracy of sentinel lymph node biopsy (SLNB) after NAC in patients with ALN metastasis at diagnosis.

Methods

From January 2007 to August 2013, data of patients who were diagnosed with invasive breast cancer and ALN metastasis and treated with NAC followed by definitive surgery in two centers were collected retrospectively. A total of 386 patients were enrolled and classified into five groups according to surgical procedure for the ALNs and pathologic results.

Results

At SLNB after NAC, sentinel lymph nodes (SLNs) that stained blue or were hot, including suspicious nodes, were identified; the SLN identification and false-negative rates was 96% and 10%, respectively. There was no difference in the overall survival among the groups. For patients who revealed a pathologic complete node response, there was a significant difference in the disease-free survival rate between the SLNB only and complete ALN dissection groups (p=0.031). However, the rate of axillary recurrence demonstrated no significant differences among the groups (p>0.050).

Conclusion

SLNB after NAC in breast cancer patients with initial ALN metastasis may help identify downstaging to negative nodal status and thereby reduce the surgical morbidity by avoiding standard ALN dissection.     

乳腺癌前哨淋巴结微转移检测在根治术中的应用价值

目的：通过对腑淋巴结阴性乳腺癌行前哨淋巴结（sentinel lymph node,SLN）活检,可推测全腋窝淋巴结受累状况。对常规病理检查阴性的SLN再行连续切片检查,则能更准则查明微转移的有无,以更可靠地评价该项技术作为设计治疗依据的价值。方法：对本组52例采用染料法（1％PatentBlueV）检出SLN,并对阴性的SLN再行连续切片,检查有无常规病理检查未能发现的微转移。结果：52例中检出SLN44例（84．6％）,检出率与肿瘤部位（P＜0．01）相关。常规病理检查是SLN（＋）13例,SLN（－）31例,此31例中有“跳跃转移”2例。总诊断符合率95．5％,假阴性率13．3％。对31例阴性SLN行连续切片测微转移,在无“跳跃转移”的29例中又检出3例阳性,假阴性率降至11．1％。结论：SLN活检对评估全腑淋巴结受累状态有一定价值,可作为选择术式及术后治疗方案的参考。本组常规病理假阴性率为13．3％,与大多数研究结果相符,此为影响该项技术应用于临床的主要障碍。本研究采用连续切片出常规法难以发现的微转移,减少了假阴性。若再结合免疫组化及RT－PCR技术,将能进一步提高SLN勘测技术的可靠性。